Dicerna Pharmaceuticals Inc, a maker of RNAi therapeutics, has secured $70 million in convertible preferred stock financing. Bain Capital Life Sciences was the lead investor. Other participants in the financing included EcoR1 Capital, Cormorant Asset Management, RA Capital, Domain Associates and Skyline Ventures. In conjunction with the funding, Dr. Adam M. Koppel, a managing director at Bain Capital Life Sciences, has been added to Dicerna’s board of directors.